Arcutis Q2 net income $15M, revenue $129.9M (+59% YoY); raises FY guidance; CCO resigns

Arcutis Biotherapeutics, Inc.

Q2 net product revenue $129.9M (+59% YoY, +23% QoQ); net income $15.0M ($0.11 EPS) vs net loss $15.9M in Q2 2025.
Raised FY2026 net product sales guidance to $525M-$540M from $480M-$495M.
FDA approved ZORYVE cream 0.3% for children aged 2+; sNDA accepted for ZORYVE cream 0.05% in infants (PDUFA Feb 23, 2027).
CCO L. Todd Edwards resigns effective Aug 21; Robert Lisicki appointed interim CCO (base $555K, equity grants).
Positive operating cash flow $12.6M; cash $238.9M.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Robert Lisicki

interim chief commercial officer

ARQT · Arcutis Biotherapeutics, Inc.

Effective: 2026-08-21
Filed: August 5, 2026, 4:14 PM ET

has appointed Robert Lisicki as interim executive vice president, starting August 17, 2026, and as interim chief commercial officer, effective upon Mr. Edwards’ departure from the Company on August 21, 2026.

Departed

L. Todd Edwards

chief commercial officer

ARQT · Arcutis Biotherapeutics, Inc.

Effective: 2026-08-21
Successor: Robert Lisicki
Filed: August 5, 2026, 4:14 PM ET

On July 31, 2026, L. Todd Edwards notified Arcutis Biotherapeutics, Inc. (the “Company”) of his decision to resign as chief commercial officer of the Company, effective as of August 21, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Lisicki was appointed as interim chief commercial officer at Arcutis Biotherapeutics, Inc..

Action: appointed
Role: interim chief commercial officer

Exact text from the filing

has appointed Robert Lisicki as interim executive vice president, starting August 17, 2026, and as interim chief commercial officer, effective upon Mr. Edwards’ departure from the Company on August 21, 2026.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

L. Todd Edwards resigned as chief commercial officer at Arcutis Biotherapeutics, Inc..

Action: resigned
Role: chief commercial officer

Exact text from the filing

On July 31, 2026, L. Todd Edwards notified Arcutis Biotherapeutics, Inc. (the “Company”) of his decision to resign as chief commercial officer of the Company, effective as of August 21, 2026.

View on SEC.gov

Arcutis Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001787306-26-000049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.